Products
Companies
News
About
About
FAQ
Contact
Contact
Newsletter
×
Subscribe to our monthly newsletter
Subscribe
Products
NeuroQuant MS
NeuroQuant MS
Cortechs.ai
NeuorQuant MS is an automated imaging software aimed at assisting physicians in their clinical evaluation process, treatment planning, and monitoring of neurodegenerative diseases by combining T2 FLAIR with 3D T1 scans for lesion and structure quantification. It automatically segments, counts, and visualizes lesions, and quantifies lesion volume changes and brain volume changes.
Information source:
Vendor
Last updated:
May 7, 2021
General Information
Technical Specifications
Regulatory
Market
Evidence
General Information
General
Product name
NeuroQuant MS
Company
Cortechs.ai
Subspeciality
Neuro
Modality
MR
Disease targeted
Multiple sclerosis, neurodegenerative diseases
Key-features
Lesion counts and volumes for new, enlarging, stable, and shrinking lesions, lesion burden calculation, normative data comparisons, longitudinal change data for lesions (per region) and brain structures, lesion change summary
Suggested use
Before: flagging acute findings
During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand)
Technical Specifications
Data characteristics
Population
All MR series where lesions are suspected
Input
3D T1 MR sequence, 3D or 2D T2 MR sequence
Input format
DICOM
Output
Lesion and brain structure segmentation overlays, lesion and brain change overlays, quantitative report with volumetric results
Output format
DICOM
Technology
Integration
Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment
Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis
On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time
> 10 minutes
Regulatory
Certification
CE
Certified, Class IIa
, MDD
FDA
510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)
Market
Market presence
On market since
08-2006
Distribution channels
Blackford, Nuance PIN, Eureka Clinical AI, Olea Medical, GE Healthcare, GMP, Getz Healthcare, Philips AI Manager
Countries present (clinical, non-research use)
43
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model
Pay-per-use, Subscription
Based on
Number of installations, Number of analyses
Evidence
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Poster: Performance evaluation for automated lesion segmentation tool: LesionQuant
(read)
White paper: LesionQuant Performance Evaluation - Accuracy and Reproducibility
(read)
Other relevant papers